Search

Your search keyword '"Mele Dario Antonio"' showing total 3 results
Start Over Author "Mele Dario Antonio" Topic asthma
3 results on '"Mele Dario Antonio"'

1. Dupilumab in the treatment of severe uncontrolled chronic rhinosinusitis with nasal polyps): a multicentric observational phase IV real‐life study (DUPIREAL)

Author

De Corso Eugenio, Pasquini, Ernesto, Trimarchi, Matteo, La Mantia Ignazio, Pagella, Fabio, Ottaviano, Giancarlo, Garzaro, Massimiliano, Pipolo, Carlotta, Torretta, Sara, Seccia, Veronica, Cantone, Elena, Ciofalo, Andrea, Lucidi, Daniela, Fadda Gian Luca, Pafundi Pia Clara, Settimi, Stefano, Montuori, Claudio, Anastasi, Francesca, Pagliuca, Giulio, Ghidini, Angelo, Cavaliere, Carlo, Maffei, Marianna, Bussu, Francesco, Gallo, Stefania, Canevari Frank Rikki Mauritz, Paludetti, Gaetano, Galli, Jacopo, Spanu, Camilla, Porru Davide Paolo, Lo Verde Simone, Corbò, Marco, Cantiani, Alessandro, Furno, Daniela, D’Agostino, Giuseppe, D’Auria Leandro Maria, De Maio Gabriele, Di Bella Giuseppe Alberto, Penazzi, Daniele, Mele Dario Antonio, Di Cesare Tiziana, Andrea, Rampi, Umberto, Tanzini, Saccardo, Tommaso, Roccuzzo, Giuseppe, Cipolla, Federica, Ragusa, Martina, Grigaliute, Egle, Alicandri Ciufelli Matteo, Roncadi, Leonardo, Rizzo, Davide, De Vita Carla, Farneti, Paolo, Todero, Gabriella, Cristofani‐mencacci, Lodovica, Statuti, Erica, Cavallo, Giovanni, Urbanelli, Anastasia, Ferrella, Francesco, Arnone, Flavio, Di Nola Claudio, Pignataro, Lorenzo, Nava, Nicolò, Russo, Paolo, Savastano, Vincenzo, Masieri, Simonetta, Dell’Era, Valeria, Aluffi Valletti Paolo, Sovardi, Fabio, Siragusa, Vera, Clemenzi, Veronica, Stolfa, Andrea, Simoni, Edi, and Astolfi, Laura

Subjects
dupilumab, smell, biologics, dupireal, crswnp, asthma, biologics, chronic rhinosinusitis with nasal polyps, dupilumab, smell, asthma, chronic rhinosinusitis with nasal polyps
Published
2023

2. Antileukotrienes improve naso-ocular symptoms and biomarkers in patients with NARES and asthma

Author

De Corso, Eugenio, Anzivino, R, Galli, Jacopo, Baroni, Silvia, Di Nardo, Walter, De Vita, C, Salvati, Alessandra, Autilio, C, Settimi, Stefano, Mele, Dario Antonio, Paludetti, Gaetano, and Mullol, J

Subjects
Adult, Cyclopropanes, Male, antileukotrienes, Eye Diseases, precision medicine, Syndrome, Acetates, Sulfides, Asthma, montelukast, Eosinophilia, Nose Diseases, Quinolines, Humans, Leukotriene Antagonists, Female, eosinophils, Settore MED/31 - OTORINOLARINGOIATRIA, Prospective Studies, eotaxin, Biomarkers, Rhinitis
Abstract

The aim of our study was to analyze the montelukast effectiveness in improving oculonasal symptoms, patient-reported outcomes (PROs), and eosinophilic biomarkers in patients with nonallergic rhinitis eosinophilic syndrome (NARES).We enrolled prospectively 80 symptomatic patients treated with 10 mg once a day of montelukast in monotherapy for 2 months. All patients were investigated before and after treatment. Nasal symptoms (nasal obstruction, rhinorrhoea, sneezing, nasal itching), ocular symptoms (redness/puffiness, watery eyes), and other PROs (olfactory dysfunction, difficulty going to sleep, nighttime awakenings, and nasal congestion on awakening) were scored by visual analogic scale. The following clinical scores were assessed: Total Nasal Symptom Score (T4NSS), Total Ocular Symptom Score (T2OSS), Total Symptom Score of Patient-Reported Outcomes (TSS-PROs), and a Composite Symptoms Score (CSS). Patients were classified as responders when a reduction of at least 50% of the CSS was observed. Before and after treatment, the eosinophilic biomarkers in nasal lavage were analyzed: nasal eosinophilia (number of eosinophils per high power field), eotaxin-1 and eotaxin-2.After treatment, significant reductions were observed for all the symptom scores. Forty-two of 78 patients were considered responders. A significant reduction of eosinophils in nasal mucosa and of levels of eotaxin-1 and eotaxin-2 in nasal lavage were observed after treatment in responder patients. Patients with asthma had an increased probability to be responders.NARES patients may benefit from treatment with montelukast. In particular, the presence of concomitant asthma may be predictive of a greater efficacy.2 Laryngoscope, 129:551-557, 2019.

Published
2018

3. Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.

Author

De Corso, Eugenio, Montuori, Claudio, Settimi, Stefano, Mele, Dario Antonio, Cantiani, Alessandro, Corbò, Marco, Cantone, Elena, Paludetti, Gaetano, and Galli, Jacopo

Subjects
OTITIS media, OTITIS media with effusion, NASAL polyps, ASTHMA, HEARING levels, BIOLOGICALS, DRUG efficacy
Abstract

Eosinophilic otitis media (EOM) is a difficult-to-treat otitis media characterized by eosinophilic accumulation in the middle ear mucosa and effusion. It is resistant to conventional treatments and strongly associated with asthma and chronic rhinosinusitis with nasal polyps (CRSwNP). The aim of our study is to evaluate the effectiveness of biologics drugs in the control of EOM. This is a retrospective no-profit real-life observational study, involving patients affected by refractory EOM and in treatment with different biologics for concomitant severe eosinophilic asthma or severe uncontrolled CRSwNP (Dupilumab: n = 5; Omalizumab: n = 1; Mepolizumab: n = 1; Benralizumab: n = 1). We analyzed data at baseline and at the 6-month follow-up, including specific nasal and otological parameters. We observed an improvement of all nasal outcomes, including NPS, SNOT-22, VAS, and smell function. Regarding specific otological parameters, we observed a significant reduction in the mean value of COMOT-15 score and of Otitis Severity Score at 6-month follow-up compared to baseline (p < 0.05). Finally, we observed an improvement in terms of air conduction hearing levels during the treatment. Our results demonstrated that anti type-2 inflammatory pathway biologics can be effective in improving symptoms control and in reducing the severity of eosinophilic otitis media when treating coexisting type-2 diseases, such as asthma and or CRSwNP. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results